Products for Research Use Only
RegisterLogin

(S) -CR8

CAT: 0804-HY-112371-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112371-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(S) -CR8 is the S-isomer of CR8. (S) -CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S) -CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM) [1].
CAS Number
1084893-56-0
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/s-cr8.html
Purity
99.0
Solubility
DMSO : ≥ 50 mg/mL
Smiles
CC[C@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO
Molecular Formula
C24H29N7O
Molecular Weight
431.53
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27 (44) :5797-807.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-18340-01(R) ​-​CR8
HY-18340A-01(R) -CR8 (trihydrochloride)
HY-125845B(S, S, S) -AHPC
HY-120217A(S, S, S) -VH032
HY-172298(R, S, S, S) -Orlistat
HY-112078B(S, S, S) -AHPC-Me
HY-123109A-01(S, S, S) -AHPC-Boc
HY-125845A-01(S, S, S) -AHPC (hydrochloride)
HY-78931B-01(S, S, S, S, R) -Boc-Dap-NE
HY-137428-01(S, S) -EDDS

Alternative Products

CatalogName
562570(S)-CR8
GL4189-10mg(S) -CR8
T12617L-01(R) ​-​CR8
GL2908-1mg(R) -CR8
3605/10(R)-CR8
406333CR8 hydrochloride
045264-01S-CR8
BUP04845-01(R) ?-?CR8
abx283296-01CR8 3HCl (R)
A24446-50(R) -CR8 50mg

Popular Products